A team led by UCLA scientists found that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone.
UCLA researchers discover that MAOIs could activate immune system to shrink various types of tumors.
The research, conducted on mice, targets a newly discovered molecular “checkpoint” that enables cancer stem cells to evade the immune system.
Overweight children participating in the intervention were 70% less likely to have detectable cancer cells after one month of treatment.
Only 1 in 10 people diagnosed with this aggressive disease live beyond five years, and most current therapies have been unsuccessful in treating it.
The study, conducted in mice, opens a path for exploring treatments that combine epigenetic approaches with therapies that use the body’s natural immune response.
Research brief: Improving imaging processes will lead to more successful treatments and help reduce morbidity in men with the disease.
Research brief: The new finding highlights the need for alternative therapies for patients who are resistant to chemotherapy and radiation.
The new method should become the standard of care, say researchers from both universities who validated its effectiveness.
UCLA research paves the way for new diagnostic and therapeutic approaches.
In memoriam: Helene Brown, 91, ‘political oncologist’ who campaigned for cancer research, prevention
Brown, a UCLA alumna and member of UCLA’s Jonsson Comprehensive Cancer Center, died Oct. 4 at her home in Los Angeles.
Since first appearing in 2011, #BCSM has been used on the social media platform more than 830,000 times.
A pioneer in cancer immunology, Dr. Antoni Ribas has devoted his career to developing and refining new therapies for malignant melanoma.
The research opens up the possibility of using drugs that simulate viruses to overcome immunotherapy resistance in melanoma.
Spanning medicine, math and nanomaterials, support for campus scientific studies has grown almost 40% in five years.
The team will investigate the mechanisms of treatment resistance, laying the groundwork for new and improved combination therapies.
One of the most effective preventive measures is germline sequencing, which can detect gene mutations known to increase disease risk.
Research brief: UCLA researchers found that chemotherapy is often underutilized when treating adults with sarcoma, a rare type of cancer of the soft tissues or bone.
Research brief: A new combination treatment shows success in a mouse model of advanced head and neck carcinoma.
Research brief: A study shows that while both are factors, a higher proportion of physicians report patients' safety as a concern.
Research brief: A study shows that the proportion of vaccinated adolescents is higher in most states that require students to receive the vaccine.
The award from the National Cancer Institute will fund a series of collaborative research projects over five years at UCLA.
The immunotherapy drug combination is currently being reviewed for approval under a new FDA pilot program.
By repurposing drugs originally intended for other uses, scientists are pushing forward the fight against cancer.
“We hope our method could be used in the future to prepare treatments that can be performed at the patient’s bedside,” said UCLA’s Paul Weiss.